FBN2 and cancer: Badr et al. (2022) state that multiple accumulated weak mutations can combine to form a polygenic conductor (main driver) with enough impact to modify cellular function and patient prognosis (Badr et al., 2022), as depicted in Fig. 6. Our findings indicate that patients with mutations in DOCK3, FN1, PAPPA2, DNAH11, and FBN2 genes had a shorter survival rate compared to patients without mutations. These results suggest that these alterations lead to cell dysregulation, as seen in other cancer types (Irmak-Yazicioglu, 2016; Wilk & Braun, 2018; Furuya et al., 2021).